Docetaxel, Capecitabine, Cisplatin, Bevacizumab — Competitive Intelligence Brief

Docetaxel, Capecitabine, Cisplatin, Bevacizumab (Docetaxel, Capecitabine, Cisplatin, Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane, Thymidylate synthase inhibitor, Platinum-based alkylating agent, Monoclonal antibody. Area: Oncology.

phase 2 Taxane, Thymidylate synthase inhibitor, Platinum-based alkylating agent, Monoclonal antibody Microtubules, Thymidylate synthase, DNA, Vascular endothelial growth factor Oncology Small molecule

Target snapshot

Docetaxel, Capecitabine, Cisplatin, Bevacizumab (Docetaxel, Capecitabine, Cisplatin, Bevacizumab) — Asan Medical Center. Docetaxel is a microtubule inhibitor that disrupts cell division, Capecitabine is a thymidylate synthase inhibitor that interferes with DNA synthesis, Cisplatin is a platinum-based alkylating agent that cross-links DNA, Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Docetaxel, Capecitabine, Cisplatin, Bevacizumab TARGET	Docetaxel, Capecitabine, Cisplatin, Bevacizumab	Asan Medical Center	phase 2	Taxane, Thymidylate synthase inhibitor, Platinum-based alkylating agent, Monoclonal antibody	Microtubules, Thymidylate synthase, DNA, Vascular endothelial growth factor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane, Thymidylate synthase inhibitor, Platinum-based alkylating agent, Monoclonal antibody class)

1. Asan Medical Center · 1 drug in this class